{
    "root": "b4189f1e-1926-47a2-9fdf-308b500377a3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "BRAFTOVI",
    "value": "20250321",
    "ingredients": [
        {
            "name": "ENCORAFENIB",
            "code": "8L7891MRB6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11718"
        },
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_78913"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32026"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SUCCINIC ACID",
            "code": "AB6MNQ6J6L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15741"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        }
    ],
    "indications": {
        "text": "braftovi kinase inhibitor indicated : melanoma \u2022 combination binimetinib , treatment patients unresectable metastatic melanoma braf v600e v600k mutation , detected fda-approved test . ( 1.1 , 2.1 ) colorectal cancer ( crc ) \u2022 combination cetuximab mfolfox6 , treatment patients metastatic colorectal cancer ( mcrc ) braf v600e mutation , detected fda\u2011approved test . ( 1.2 , 2.1 ) indication approved accelerated approval based response rate durability response [ ( 14.2 ) ] . continued approval indication may contingent upon verification description benefit confirmatory trial ( ) . \u2022 combination cetuximab , treatment adult patients metastatic crc braf v600e mutation , detected fda-approved test , prior therapy . ( 1.2 , 2.1 ) non-small cell lung cancer ( nsclc ) \u2022 combination binimetinib , treatment adult patients metastatic non-small cell lung cancer ( nsclc ) braf v600e mutation , detected fda-approved test . ( 1.3 , 2.1 ) limitations braftovi indicated treatment patients wild-type braf melanoma , wild-type braf crc , wild-type braf nsclc . ( 1.4 , 5.2 )",
        "doid_entities": [
            {
                "text": "melanoma (DOID:1909)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1909"
            },
            {
                "text": "colorectal cancer (DOID:9256)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9256"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "non-small cell lung cancer (DOID:3908)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3908"
            },
            {
                "text": "lung cancer (DOID:1324)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1324"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "melanoma \u2022 confirm presence braf v600e v600k mutation tumor specimens prior initiation braftovi . ( 2.1 ) \u2022 recommended dose 450 mg orally daily combination binimetinib . ( 2.2 ) crc \u2022 confirm presence braf v600e mutation plasma tumor specimens prior initiation braftovi . ( 2.1 ) \u2022 recommended dose 300 mg orally daily combination cetuximab . ( 2.3 ) nsclc \u2022 confirm presence braf v600e mutation tumor plasma specimens prior initiating braftovi . ( 2.1 ) \u2022 recommended dose 450 mg orally daily combination binimetinib . ( 2.2 ) take braftovi without food . ( 2.4 )",
        "doid_entities": [
            {
                "text": "melanoma (DOID:1909)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1909"
            },
            {
                "text": "nsclc (DOID:3908)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3908"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "braftovi ( encorafenib ) supplied 75 mg hard gelatin capsules . 75 mg : stylized `` `` beige cap `` lgx 75mg `` white body , available cartons ( ndc 70255-025-01 ) containing two bottles 90 capsules ( ndc 70255-025-02 ) cartons ( ndc 70255-025-03 ) containing two bottles 60 capsules ( ndc 70255-025-04 ) .",
    "adverseReactions": "none .",
    "indications_original": "BRAFTOVI is a kinase inhibitor indicated: Melanoma \u2022 in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) \u2022 in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA\u2011approved test. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). \u2022 in combination with cetuximab, for the treatment of adult patients with metastatic CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Non-Small Cell Lung Cancer (NSCLC) \u2022 in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.3 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. ( 1.4 , 5.2 )",
    "contraindications_original": "Melanoma \u2022 Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to the initiation of BRAFTOVI. ( 2.1 ) \u2022 The recommended dose is 450 mg orally once daily in combination with binimetinib. ( 2.2 ) CRC \u2022 Confirm the presence of BRAF V600E mutation in plasma or tumor specimens prior to the initiation of BRAFTOVI. ( 2.1 ) \u2022 The recommended dose is 300 mg orally once daily in combination with cetuximab. ( 2.3 ) NSCLC \u2022 Confirm the presence of BRAF V600E mutation in tumor or plasma specimens prior to initiating BRAFTOVI. ( 2.1 ) \u2022 The recommended dose is 450 mg orally once daily in combination with binimetinib. ( 2.2 ) Take BRAFTOVI with or without food. ( 2.4 )",
    "warningsAndPrecautions_original": "BRAFTOVI (encorafenib) is supplied as 75 mg hard gelatin capsules.\n                  75 mg: stylized \"A\" on beige cap and \"LGX 75mg\" on white body, available in cartons (NDC 70255-025-01) containing two bottles of 90 capsules each (NDC 70255-025-02) and cartons (NDC 70255-025-03) containing two bottles of 60 capsules each (NDC 70255-025-04).",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "BRAFTOVI",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11718"
        }
    ]
}